OneCell Diagnostics

High-Level Overview

OneCell Diagnostics is a genomics-based precision oncology company developing 1st-in-Class Circulating Tumor Cell (CTC)-based, Single-Cell Multi-omics liquid biopsy tests for clinical cancer care and early-stage clinical trials for biotech/pharma companies.[1][2][4] It builds proprietary cell biopsy technology that integrates CTC-DNA, CTC-RNA, and cell surface protein testing from a single blood draw, enabling more accessible, actionable, and affordable cancer diagnostics compared to traditional methods.[1][4] The company serves cancer patients, clinicians, and biotech/pharma firms, addressing the problem of limited precision in current liquid biopsies by leveraging AI, next-generation sequencing, bioinformatics, and multi-omics biomarkers for better cancer management.[1][3][4] With $16M in oversubscribed Series A funding raised in 2024 (led by Celesta Capital), OneCell demonstrates strong growth momentum, headquartered in Silicon Valley and India, and recently partnering with AccuGenomics for Asia expansion and U.S. plans.[4][5]

Origin Story

OneCell Diagnostics was founded in 2021 as a joint venture between Actorius Innovations and Research Pvt Ltd (a leading CTC test provider in India) and Indx.ai (a Silicon Valley software firm specializing in multi-omics biomarker data analytics).[1] Mohan Uttarwar serves as CEO and Co-Founder, with a Chief Operating Officer & Co-Founder also noted in leadership.[1][4] The idea emerged from combining innovative CTC isolation technologies with AI-driven analytics to create comprehensive genomic solutions for precision oncology, filling gaps in existing cancer diagnostics.[1][3] Early traction includes developing its proprietary platform and securing $16M in Series A funding in 2024, validating its vision amid rising demand for advanced liquid biopsies.[4]

Core Differentiators

• Proprietary CTC-Based Single-Cell Multi-Omics Platform: Integrates DNA, RNA, and protein analysis from circulating tumor cells in one blood draw, advancing beyond standard liquid biopsies for higher accuracy in cancer screening and monitoring.[1][2][4]
• AI and Bioinformatics Integration: Uses advanced AI/ML with next-generation sequencing for multi-omics biomarker analytics, enabling personalized, actionable insights in clinical care and trials.[1][3][4][5]
• Accessibility and Affordability: Focuses on democratizing precision oncology with cost-effective, scalable tests deployable globally, supported by operations in Silicon Valley and India.[1][4]
• Strategic Partnerships and Expansion: Recent collaboration with AccuGenomics enhances ultra-sensitive testing across Asia with U.S. plans, boosting reach and validation.[5]

Role in the Broader Tech Landscape

OneCell rides the precision oncology and liquid biopsy trend, where multi-omics and AI are transforming cancer care from reactive to proactive, personalized management.[1][3][4][5] Timing is ideal amid surging demand for non-invasive diagnostics post-COVID, with market forces like aging populations, rising cancer incidence, and biotech trial needs favoring scalable CTC tech over tissue biopsies.[4] By enabling single-draw, comprehensive testing, OneCell influences the ecosystem through partnerships (e.g., AccuGenomics), funding from deep-tech investors like Celesta Capital, and exhibitions at events like PMWC, accelerating adoption in clinical and pharma settings.[2][4][5]

Quick Take & Future Outlook

OneCell is poised to scale its platform globally, leveraging Series A funds for commercialization, U.S. expansion, and further AI enhancements to capture liquid biopsy market share.[4][5] Trends like AI-multi-omics integration and Asia's oncology boom will shape its path, potentially evolving it into a leader in democratized cancer diagnostics with broader biotech trial impacts.[1][4][5] Watch for FDA validations and pharma deals tying back to its core mission of accessible precision care.